New research from the USDA Forest Service, Cornell Lab of Ornithology, and University of New Mexico identifies where future high-severity fires threaten biodiversity hotspots in the western United States using observations from bird watchers and advanced fire forecasting models.
VersaWater, a Cornell-led initiative, is addressing one of the nation’s most persistent gaps in water access: the lack of reliable, affordable drinking water in small and rural communities.
Ari Novy, Ph.D., a plant scientist, science educator, and leader in botanic-garden management, was named executive director of Cornell Botanic Gardens. He comes to Cornell from San Diego Botanic Gardens, where he served as president and CEO, and also was adjunct associate professor at the Salk Institute for Biological Studies in La Jolla, California.
While the number of U.S. work stoppages decreased overall by nearly 16% over the past year, the health care industry saw a 58.3% jump in work stoppages and a 151.9% increase in the number of workers involved.
In her new book, Kim Haines-Eitzen explores the fourth Gospel of the New Testament, which holds many of the Bible’s most well-known passages but is also at the root of many controversies.
Major search platforms may strategically obfuscate search results — placing certain items in prime positions on their sites, for example — to increase profits, a study from the Cornell SC Johnson College of Business finds.
Bram Govaerts, director general of the International Maize and Wheat Improvement Center, will kick off the A.D. White Professors-at-Large spring 2026 visits with a pair of talks addressing agri-food research and innovation.
A grant from the Teagle Foundation will allow Cornell faculty and staff to launch a new civic education program for high school students, opening pathways to higher education.
Five Cornell faculty members are among 126 early-career researchers across North America who have won 2026 Sloan Research Fellowships from the Alfred P. Sloan Foundation.
Immunotherapy has not worked well against fibrolamellar carcinoma, but a new study finds an existing FDA-approved drug may allow the treatment to fight the cancer as intended.
